Literature DB >> 20698170

Polymorphisms in Toll-like receptor genes--implications for prostate cancer development.

Zeljko Vidas1.   

Abstract

Toll-like receptors are key players in initiation of innate immune response of the host. In addition to innate immunity they can also induce adaptive immune responses. The concept that inflammation can promote chronic prostatic diseases, such as benign prostatic hyperplasia or prostate carcinoma is supported by several new findings. Epidemiological data have correlated prostatitis with an increased risk of prostate cancer, while PCR-based analyses of bacterial colonization in prostate cancer specimens and normal prostate tissue showed high correlation of bacterial colonization and chronic inflammation with a diagnosis of prostate carcinoma. Even evidence from genetic studies support the hypothesis that prostate inflammation may be a cause of prostate cancer. From these points of view identification of factors, such as SNPs in TLR genes, associated with risk for prostate carcinoma development seems reasonable. Consequently, there are many investigations showing the connection between SNPs in TLR genes and pronounced susceptibility to different diseases. In this article we review the key findings about the genetic variability of TLR genes and prostate cancer risk.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20698170

Source DB:  PubMed          Journal:  Coll Antropol        ISSN: 0350-6134


  5 in total

1.  A missense polymorphism (rs11466653, Met326Thr) of toll-like receptor 10 (TLR10) is associated with tumor size of papillary thyroid carcinoma in the Korean population.

Authors:  Su Kang Kim; Hae Jeong Park; Il Ki Hong; Joo-Ho Chung; Young Gyu Eun
Journal:  Endocrine       Date:  2012-11-03       Impact factor: 3.633

2.  Inherited variation in pattern recognition receptors and cancer: dangerous liaisons?

Authors:  Anton G Kutikhin; Arseniy E Yuzhalin
Journal:  Cancer Manag Res       Date:  2012-02-16       Impact factor: 3.989

Review 3.  The Pathologic Role of Toll-Like Receptor 4 in Prostate Cancer.

Authors:  Tongwen Ou; Michael Lilly; Wei Jiang
Journal:  Front Immunol       Date:  2018-06-06       Impact factor: 7.561

Review 4.  Toll-like receptor signaling in hematopoietic homeostasis and the pathogenesis of hematologic diseases.

Authors:  Joseph Cannova; Peter Breslin S J; Jiwang Zhang
Journal:  Front Med       Date:  2015-08-22       Impact factor: 4.592

Review 5.  Should a Toll-like receptor 4 (TLR-4) agonist or antagonist be designed to treat cancer? TLR-4: its expression and effects in the ten most common cancers.

Authors:  Chun Wai Mai; Yew Beng Kang; Mallikarjuna Rao Pichika
Journal:  Onco Targets Ther       Date:  2013-11-05       Impact factor: 4.147

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.